{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:54:15Z","timestamp":1793534055076,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Program in Clinical Research at the University of Helsinki"},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Program of the Faculty of Medicine, University of Helsinki"},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Helsinki University Central Hospital research funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conventional chemotherapeutic agents are nonselective, often resulting in severe side effects and the development of resistance. Therefore, new molecular-targeted therapies are urgently needed to be integrated into existing treatment regimens. Here, we performed a high-throughput compound screen to identify a synergistic interaction between ionizing radiation and 396 anticancer compounds. The assay was run using five human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) cell lines cultured on the human tumor-derived matrix Myogel<jats:italic>.<\/jats:italic> Our screen identified several compounds with strong synergistic and antagonistic effects, which we further investigated using multiple irradiation doses. Navitoclax, which emerged as the most promising radiosensitizer, exhibited synergy with irradiation regardless of the p53 mutation status in all 13 HNSCC cell lines. We performed a live cell apoptosis assay for two representative HNSCC cell lines to examine the effects of navitoclax and irradiation. As a single agent, navitoclax reduced proliferation and induced apoptosis in a dose-dependent manner, whereas the navitoclax\u2013irradiation combination arrested cell cycle progression and resulted in substantially elevated apoptosis. Overall, we demonstrated that combining navitoclax with irradiation resulted in synergistic in vitro antitumor effects in HNSCC cell lines, possibly indicating the therapeutic potential for HNSCC patients.<\/jats:p>","DOI":"10.1038\/s41598-021-94259-5","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:26:57Z","timestamp":1626776817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Katja","family":"Tuomainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aini","family":"Hyyti\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ianevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Ianevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Kuznetsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Risteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"M\u00e4kitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Monni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"94259_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209-249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"94259_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7\u201330 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"94259_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14728214.2015.1031653","volume":"20","author":"Y Wen","year":"2015","unstructured":"Wen, Y. & Grandis, J. R. Emerging drugs for head and neck cancer. Expert Opin. Emerg. Drugs 20, 313\u2013329 (2015).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"94259_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","volume":"8","author":"L Hutchinson","year":"2011","unstructured":"Hutchinson, L. & Kirk, R. High drug attrition rates\u2014Where are we going wrong?. Nat. Rev. Clin. Oncol. 8, 189\u2013190 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"94259_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1186\/s12885-015-1944-z","volume":"15","author":"T Salo","year":"2015","unstructured":"Salo, T. et al. A novel human leiomyoma tissue derived matrix for cell culture studies. BMC Cancer 15, 981 (2015).","journal-title":"BMC Cancer"},{"issue":"1737","key":"94259_CR6","doi-asserted-by":"publisher","first-page":"20160482","DOI":"10.1098\/rstb.2016.0482","volume":"373","author":"T Salo","year":"2018","unstructured":"Salo, T. et al. Organotypic three-dimensional assays based on human leiomyoma-derived matrices. Philos. Trans. R Soc. Lond. B Biol. Sci. 373(1737), 20160482. https:\/\/doi.org\/10.1098\/rstb.2016.0482 (2018).","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"issue":"1","key":"94259_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers12010092","volume":"12","author":"K Tuomainen","year":"2019","unstructured":"Tuomainen, K. et al. Human tumor-derived matrix improves the predictability of head and neck cancer drug testing. Cancers (Basel) 12(1), 92.\nhttps:\/\/doi.org\/10.3390\/cancers12010092 (2019).","journal-title":"Cancers (Basel)"},{"key":"94259_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"94259_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324\u20131337 (2007).","journal-title":"Oncogene"},{"key":"94259_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 25, 65\u201380 (2018).","journal-title":"Cell Death Differ."},{"key":"94259_CR11","doi-asserted-by":"publisher","first-page":"e1437","DOI":"10.1038\/cddis.2014.415","volume":"5","author":"L Chang","year":"2014","unstructured":"Chang, L. et al. PI3K\/Akt\/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 5, e1437 (2014).","journal-title":"Cell Death Dis."},{"key":"94259_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans, C. R., Braakhuis, B. J. M. & Brakenhoff, R. H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9\u201322 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"94259_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/sj.cdd.4401962","volume":"13","author":"MT Hemann","year":"2006","unstructured":"Hemann, M. T. & Lowe, S. W. The p53-Bcl-2 connection. Cell Death Differ. 13, 1256\u20131259 (2006).","journal-title":"Cell Death Differ."},{"key":"94259_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini, G. F., Ribeiro, G. N., Pinto Neto, J. V., Campos, L. T. & Hamerschlak, N. BCL-2 as therapeutic target for hematological malignancies. J. Hematol. Oncol. 11, 65 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"94259_CR15","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"94259_CR16","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1002\/lary.28441","volume":"130","author":"TJ Ow","year":"2020","unstructured":"Ow, T. J. et al. Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. Laryngoscope 130, 2643\u20132649 (2020).","journal-title":"Laryngoscope"},{"key":"94259_CR17","doi-asserted-by":"publisher","first-page":"e0219398","DOI":"10.1371\/journal.pone.0219398","volume":"14","author":"EL Britt","year":"2019","unstructured":"Britt, E. L. et al. Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. PLoS One 14, e0219398 (2019).","journal-title":"PLoS One"},{"key":"94259_CR18","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1158\/1535-7163.MCT-17-0733","volume":"17","author":"T Lepikhova","year":"2018","unstructured":"Lepikhova, T. et al. Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy. Mol. Cancer Ther. 17, 2060\u20132071 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"94259_CR19","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).","journal-title":"Sci. Rep."},{"key":"94259_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","volume":"1711","author":"L He","year":"2018","unstructured":"He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. Methods Mol. Biol. 1711, 351\u2013398 (2018).","journal-title":"Methods Mol. Biol."},{"key":"94259_CR21","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: Visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucleic Acids Res."},{"key":"94259_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.18632\/oncotarget.26563","volume":"10","author":"TJ Ow","year":"2019","unstructured":"Ow, T. J. et al. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget 10, 494\u2013510 (2019).","journal-title":"Oncotarget"},{"key":"94259_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41419-019-2150-8","volume":"10","author":"RJ Carter","year":"2019","unstructured":"Carter, R. J. et al. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck. Cell Death Dis. 10, 912 (2019).","journal-title":"Cell Death Dis."},{"key":"94259_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00066-007-1696-z","volume":"183","author":"C Sch\u00fctze","year":"2007","unstructured":"Sch\u00fctze, C. et al. Combination of EGFR\/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther. Onkol. 183, 256\u2013264 (2007).","journal-title":"Strahlenther. Onkol."},{"key":"94259_CR25","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.18632\/oncotarget.15468","volume":"8","author":"MA Macha","year":"2017","unstructured":"Macha, M. A. et al. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget 8, 20961\u201320973 (2017).","journal-title":"Oncotarget"},{"key":"94259_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0360-3016(02)02865-1","volume":"53","author":"L Rossi","year":"2002","unstructured":"Rossi, L. & Corv\u00f2, R. Retinoic acid modulates the radiosensitivity of head-and-neck squamous carcinoma cells grown in collagen gel. Int. J. Radiat. Oncol. Biol. Phys. 53, 1319\u20131327 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"94259_CR27","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1158\/1078-0432.CCR-18-0401","volume":"24","author":"JH Laird","year":"2018","unstructured":"Laird, J. H. et al. Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin. Cancer Res. 24, 5143\u20135152 (2018).","journal-title":"Clin. Cancer Res."},{"key":"94259_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.radonc.2013.12.014","volume":"110","author":"C Lund-Andersen","year":"2014","unstructured":"Lund-Andersen, C., Patzke, S., N\u00e4hse-Kumpf, V. & Sylju\u00e5sen, R. G. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule. Radiother. Oncol. 110, 355\u2013361 (2014).","journal-title":"Radiother. Oncol."},{"key":"94259_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-10-441","volume":"10","author":"A Wouters","year":"2010","unstructured":"Wouters, A. et al. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 10, 441 (2010).","journal-title":"BMC Cancer"},{"key":"94259_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.oraloncology.2013.01.007","volume":"49","author":"A Argiris","year":"2013","unstructured":"Argiris, A., Pennella, E., Koustenis, A., Hossain, A. M. & Obasaju, C. K. Pemetrexed in head and neck cancer: A systematic review. Oral Oncol. 49, 492\u2013501 (2013).","journal-title":"Oral Oncol."},{"key":"94259_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/1471-2407-12-463","volume":"12","author":"H Stegeman","year":"2012","unstructured":"Stegeman, H. et al. Activation of AKT by hypoxia: A potential target for hypoxic tumors of the head and neck. BMC Cancer 12, 463 (2012).","journal-title":"BMC Cancer"},{"key":"94259_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/019459988309100503","volume":"91","author":"TE Carey","year":"1983","unstructured":"Carey, T. E. et al. Antibodies to human squamous cell carcinoma. Otolaryngol. Head Neck Surg. 91, 482\u2013491 (1983).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"94259_CR33","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013).","journal-title":"Cancer Discov."},{"key":"94259_CR34","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94259-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:14:20Z","timestamp":1670066060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94259-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94259"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94259-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14755"}}